Ikena Oncology, Inc.

NasdaqGM:IKNA Rapport sur les actions

Capitalisation boursière : US$82.5m

Ikena Oncology Gestion

Gestion contrôle des critères 2/4

Nous ne disposons actuellement pas d’informations suffisantes sur le PDG.

Informations clés

Mark Manfredi

Directeur général

US$1.2m

Rémunération totale

Pourcentage du salaire du PDG45.9%
Durée du mandat du directeur général6.9yrs
Propriété du PDGn/a
Durée moyenne d'occupation des postes de direction1.1yrs
Durée moyenne du mandat des membres du conseil d'administration4yrs

Mises à jour récentes de la gestion

Increases to CEO Compensation Might Be Put On Hold For Now at Ikena Oncology, Inc. (NASDAQ:IKNA)

Jun 01
Increases to CEO Compensation Might Be Put On Hold For Now at Ikena Oncology, Inc. (NASDAQ:IKNA)

Recent updates

Increases to CEO Compensation Might Be Put On Hold For Now at Ikena Oncology, Inc. (NASDAQ:IKNA)

Jun 01
Increases to CEO Compensation Might Be Put On Hold For Now at Ikena Oncology, Inc. (NASDAQ:IKNA)

Growth Investors: Industry Analysts Just Upgraded Their Ikena Oncology, Inc. (NASDAQ:IKNA) Revenue Forecasts By 31%

Nov 10
Growth Investors: Industry Analysts Just Upgraded Their Ikena Oncology, Inc. (NASDAQ:IKNA) Revenue Forecasts By 31%

Analysts Just Slashed Their Ikena Oncology, Inc. (NASDAQ:IKNA) EPS Numbers

Aug 15
Analysts Just Slashed Their Ikena Oncology, Inc. (NASDAQ:IKNA) EPS Numbers

Need To Know: Analysts Are Much More Bullish On Ikena Oncology, Inc. (NASDAQ:IKNA) Revenues

May 20
Need To Know: Analysts Are Much More Bullish On Ikena Oncology, Inc. (NASDAQ:IKNA) Revenues

Will Ikena Oncology (NASDAQ:IKNA) Spend Its Cash Wisely?

Apr 29
Will Ikena Oncology (NASDAQ:IKNA) Spend Its Cash Wisely?

We Think Ikena Oncology (NASDAQ:IKNA) Needs To Drive Business Growth Carefully

Jan 06
We Think Ikena Oncology (NASDAQ:IKNA) Needs To Drive Business Growth Carefully

Companies Like Ikena Oncology (NASDAQ:IKNA) Are In A Position To Invest In Growth

Aug 06
Companies Like Ikena Oncology (NASDAQ:IKNA) Are In A Position To Invest In Growth

Party Time: Brokers Just Made Major Increases To Their Ikena Oncology, Inc. (NASDAQ:IKNA) Earnings Forecasts

Mar 23
Party Time: Brokers Just Made Major Increases To Their Ikena Oncology, Inc. (NASDAQ:IKNA) Earnings Forecasts

Ikena Oncology, Inc. (NASDAQ:IKNA) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Mar 21
Ikena Oncology, Inc. (NASDAQ:IKNA) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Is Ikena Oncology (NASDAQ:IKNA) In A Good Position To Deliver On Growth Plans?

Feb 19
Is Ikena Oncology (NASDAQ:IKNA) In A Good Position To Deliver On Growth Plans?

We're Not Very Worried About Ikena Oncology's (NASDAQ:IKNA) Cash Burn Rate

Nov 02
We're Not Very Worried About Ikena Oncology's (NASDAQ:IKNA) Cash Burn Rate

Ikena Oncology (NASDAQ:IKNA) Is In A Good Position To Deliver On Growth Plans

Jul 13
Ikena Oncology (NASDAQ:IKNA) Is In A Good Position To Deliver On Growth Plans

Analyse de la rémunération des PDG

Comment la rémunération de Mark Manfredi a-t-elle évolué par rapport aux bénéfices de Ikena Oncology?
DateRémunération totaleSalaireBénéfices de l'entreprise
Sep 30 2024n/an/a

-US$60m

Jun 30 2024n/an/a

-US$67m

Mar 31 2024n/an/a

-US$70m

Dec 31 2023US$1mUS$569k

-US$68m

Sep 30 2023n/an/a

-US$63m

Jun 30 2023n/an/a

-US$63m

Mar 31 2023n/an/a

-US$66m

Dec 31 2022US$2mUS$546k

-US$69m

Sep 30 2022n/an/a

-US$52m

Jun 30 2022n/an/a

-US$49m

Mar 31 2022n/an/a

-US$41m

Dec 31 2021US$5mUS$530k

-US$34m

Sep 30 2021n/an/a

-US$63m

Jun 30 2021n/an/a

-US$55m

Mar 31 2021n/an/a

-US$47m

Dec 31 2020US$606kUS$410k

-US$44m

Rémunération vs marché: La rémunération totale de Mark ($USD 1.24M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 647.72K ).

Rémunération et revenus: La rémunération de Mark a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.


PDG

Mark Manfredi (53 yo)

6.9yrs

Titularisation

US$1,240,640

Compensation

Dr. Mark Manfredi, Ph D., serves as Member of Scientific Advisory Board of Bantam Pharmaceutical, LLC. He has been President, Chief Executive Officer and Director of Ikena Oncology, Inc. since December 201...


Équipe de direction

NomPositionTitularisationCompensationPropriété
Mark Manfredi
President6.9yrsUS$1.24mpas de données
Jotin Marango
CFO & Head of Corporate Development2.6yrsUS$782.32k0%
$ 0
Rebecca Cohen
Vice President of Investor Relationsless than a yearpas de donnéespas de données
Jeffrey Ecsedy
Chief Development Officer3yrspas de donnéespas de données
Bob Lally
Senior Vice President of Finance & Operationsno datapas de donnéespas de données
David Damphousse
Senior Vice President of Clinical Development Operations1.1yrspas de donnéespas de données
Caroline Germa
Chief Medical Officerless than a yearpas de donnéespas de données
Valdas Jurkauskas
Senior Vice President of Technical Operationsless than a yearpas de donnéespas de données

1.1yrs

Durée moyenne de l'emploi

52.5yo

Âge moyen

Gestion expérimentée: L'équipe de direction de IKNA n'est pas considérée comme expérimentée (ancienneté moyenne 1.1 ans), ce qui suggère une nouvelle équipe.


Membres du conseil d'administration

NomPositionTitularisationCompensationPropriété
Mark Manfredi
President6.9yrsUS$1.24mpas de données
Jean-Francois Formela
Independent Director8.7yrsUS$130.36k0%
$ 0
George Demetri
Chair of Scientific Advisory Board4yrspas de donnéespas de données
Otello Stampacchia
Independent Director3.9yrsUS$128.25k0%
$ 0
Neal Rosen
Member of Scientific Advisory Boardno datapas de donnéespas de données
Kevan Shokat
Member of Scientific Advisory Board4yrspas de donnéespas de données
Owen Hughes
Chairman of the Board1.8yrsUS$167.86k0%
$ 0
David Bonita
Independent Director8.7yrsUS$131.86k0%
$ 0
Iain Dukes
Independent Director8yrsUS$126.97k0%
$ 0
Richard Wooster
Independent Director2.8yrsUS$117.86k0%
$ 0
Josep Tabernero Caturla
Member of Scientific Advisory Board4yrspas de donnéespas de données
Maria Koehler
Independent Director3.6yrsUS$117.86k0%
$ 0

4.0yrs

Durée moyenne de l'emploi

62.5yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de IKNA sont considérés comme expérimentés (ancienneté moyenne 4 ans).